Fellowship · Washington, DC
Sponsored by Children's National Hospital
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer.
The New England journal of medicine · 2025 · 305 citations · Burak Gumuscu
Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children.
The New England journal of medicine · 2025 · 187 citations · Anne Angiolillo
Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023 · 447 citations · Burak Gumuscu
Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome.
Transplantation and cellular therapy · 2023 · 331 citations · Anant Vatsayan
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.
The Lancet. Oncology · 2024 · 199 citations · Burak Gumuscu
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial.
Nature medicine · 2024 · 168 citations ·
The genomic landscape of pediatric acute lymphoblastic leukemia.
Nature genetics · 2022 · 338 citations · Anne Angiolillo
Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion.
Nature reviews. Clinical oncology · 2022 · 279 citations · Sara Silbert